The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation

Over the past few years, immune checkpoint inhibitors (ICIs) have greatly improved the survival for patients with non‐small cell lung cancer (NSCLC) without driver mutations. Compared with wild‐type tumors, tumors with epidermal growth factor receptor (EGFR) mutations show more heterogeneity in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Lin, Diao, Bowen, Huang, Zhaoqin, Wang, Bin, Yu, Jinming, Meng, Xiangjiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696228/
https://www.ncbi.nlm.nih.gov/pubmed/34699691
http://dx.doi.org/10.1002/cac2.12229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696228/
https://www.ncbi.nlm.nih.gov/pubmed/34699691
http://dx.doi.org/10.1002/cac2.12229

Ejemplares similares